| Autor: |
A. A. Lyanova, L. Yu. Vladimirova, E. P. Ulyanova, N. A. Abramova, A. E. Storozhakova, I. L. Popova, N. M. Tikhanovskaya, M. A. Teplyakova, L. A. Ryadinskaya, I. A. Udalenkova, E. A. Kalabanova, S. N. Kabanov |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
South Russian Journal of Cancer. 3:40-48 |
| ISSN: |
2686-9039 |
| DOI: |
10.37748/2686-9039-2022-3-4-4 |
| Popis: |
Purpose of the study. An analysis of changes in the expression of the VEGF neoangiogenic factor in the tumor tissue of patients with squamous cell carcinoma of the oral mucosa receiving targeted therapy with cetuximab and chemotherapy.Patients and methods. We performed an immunohistochemical study of tumor samples obtained from 60 patients with squamous cell carcinoma of the oral mucosa T3-4N0-1M0. The main group comprised 30 patients who received therapy with cisplatin and fluoruracil plus cetuximab. The control group included 30 patients receiving standard chemotherapy without targeted therapy. Each group was divided into two subgroups with different treatment efficacy: patients sensitive to treatment (n = 17 in the group with cetuximab and n = 12 in the group without cetuximab) and resistant to treatment (n = 13 in the group with targeted therapy and n = 18 in the group with standard chemotherapy).Results. Quantification of the VEGF expression demonstrated minimal numbers of vessels stained positively for this marker in the field of view in patients of the main group sensitive to chemotherapy and cetuximab. The value was 5.3 times lower than initial values, and 4.3 times lower than in the subgroup of patients resistant to the treatment (the data were statistically significant, р = 0.0132 and р = 0.0455, respectively). In the control group, patients who were sensitive to the treatment showed 1.4 times lower values than initially (р = 0.921), and patients who were resistant to the treatment had 1.1 times lower values than initial values (р = 0.936). The data were not statistically significant.Conclusions. The study showed that the number of microvessels in patients resistant to chemotherapy and cetuximab was 4.3 times higher than in patients with effective targeted therapy (р = 0.0455). The differences in the control group were not statistically significant. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
